JP2023515478A5 - - Google Patents

Info

Publication number
JP2023515478A5
JP2023515478A5 JP2022549828A JP2022549828A JP2023515478A5 JP 2023515478 A5 JP2023515478 A5 JP 2023515478A5 JP 2022549828 A JP2022549828 A JP 2022549828A JP 2022549828 A JP2022549828 A JP 2022549828A JP 2023515478 A5 JP2023515478 A5 JP 2023515478A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
product according
pharmaceutical product
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022549828A
Other languages
English (en)
Japanese (ja)
Other versions
JP7745557B2 (ja
JP2023515478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019260 external-priority patent/WO2021173565A1/en
Publication of JP2023515478A publication Critical patent/JP2023515478A/ja
Publication of JP2023515478A5 publication Critical patent/JP2023515478A5/ja
Application granted granted Critical
Publication of JP7745557B2 publication Critical patent/JP7745557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022549828A 2020-02-24 2021-02-23 抗trem2抗体の使用方法 Active JP7745557B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062980929P 2020-02-24 2020-02-24
US62/980,929 2020-02-24
PCT/US2021/019260 WO2021173565A1 (en) 2020-02-24 2021-02-23 Methods of use of anti-trem2 antibodies

Publications (3)

Publication Number Publication Date
JP2023515478A JP2023515478A (ja) 2023-04-13
JP2023515478A5 true JP2023515478A5 (https=) 2024-03-01
JP7745557B2 JP7745557B2 (ja) 2025-09-29

Family

ID=74875360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549828A Active JP7745557B2 (ja) 2020-02-24 2021-02-23 抗trem2抗体の使用方法

Country Status (6)

Country Link
US (1) US20230159637A1 (https=)
EP (1) EP4110814A1 (https=)
JP (1) JP7745557B2 (https=)
CN (1) CN115768794A (https=)
CA (1) CA3167851A1 (https=)
WO (1) WO2021173565A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL296992A (en) * 2020-04-03 2022-12-01 Alector Llc Methods for using anti-trem2 antibodies
AU2021392813A1 (en) * 2020-12-04 2023-06-29 Vigil Neuroscience, Inc. Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US20090220508A1 (en) 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (en) 2007-09-14 2020-04-15 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
KR102318383B1 (ko) 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
US20190330335A1 (en) 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
CN109641961A (zh) 2016-07-22 2019-04-16 德国神经退行性疾病研究中心 Trem2切割调节剂及其用途
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
DK3601358T5 (da) * 2017-08-03 2024-09-02 Alector Llc Anti-trem2-antistoffer og fremgangsmåder til anvendelse deraf
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
WO2019068072A1 (en) * 2017-09-29 2019-04-04 The General Hospital Corporation METHODS OF IDENTIFICATION AND TREATMENT OF ADRENOMYELONEUROPATHY (AMN)
UY38407A (es) * 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CN115003699A (zh) 2019-12-05 2022-09-02 艾利妥 抗trem2抗体的使用方法
JP2023512450A (ja) * 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法

Similar Documents

Publication Publication Date Title
JP2023515478A5 (https=)
US10875909B2 (en) Humanized antibodies that recognize alpha-synuclein
JP2025069157A5 (https=)
TWI440643B (zh) 藉由投予神經生長因子拮抗劑及含彼之組合物以治療骨關節炎疼痛之方法
JP2021530960A5 (https=)
RU2006123481A (ru) Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
CN101653604A (zh) 抗ngf抗体用于治疗各种疾病
CA2478049A1 (en) Humanized antibodies that recognize beta amyloid peptide
KR20100135257A (ko) 질병 치료제
CA2494008A1 (en) Anti-myelin associated glycoprotein (mag) antibodies
US20240383980A1 (en) CD3/CD25 Antibodies For Neuro-Immune Diseases
JP2023519962A5 (https=)
JP2021534797A5 (https=)
CA3113541A1 (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
JP2023535024A5 (https=)
JP2024527401A5 (https=)
US20240417451A1 (en) Therapeutic Use of Bispecific Anti-Abeta/TfR Antibodies
JP2023177377A (ja) 多発性硬化症治療薬
WO2025070749A1 (ja) 脊髄又は脳の障害により引き起こされる疾患に伴う随伴症状の予防又は治療剤
WO2026055671A1 (en) Anti-siglec compositions and uses thereof for treating neurodegenerative diseases
RU2575629C2 (ru) Гуманизированные антитела, которые распознают альфа-синуклеин
KR20240063995A (ko) 신경퇴행성 장애를 치료하기 위한 항-세마포린-4d 결합 분자의 사용을 위한 예측 결과 프로파일링
CA3084579A1 (en) Combination therapy of multiple sclerosis comprising a cd20 ligand